NASDAQ:AUPH Aurinia Pharmaceuticals Q2 2026 Earnings Report $16.29 0.00 (0.00%) As of 08/28/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Aurinia Pharmaceuticals EPS ResultsActual EPS$0.28Consensus EPS $0.24Beat/MissBeat by +$0.04One Year Ago EPSN/AAurinia Pharmaceuticals Revenue ResultsActual Revenue$58.57 millionExpected Revenue$80.45 millionBeat/MissMissed by -$21.87 millionYoY Revenue GrowthN/AAurinia Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time8:00AM ETUpcoming EarningsAurinia Pharmaceuticals' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Quarterly report(10-Q) Aurinia Pharmaceuticals Earnings HeadlinesCould Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?August 28 at 6:00 PM | finance.yahoo.comAurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at Bloom BurtonAugust 23, 2026 | americanbankingnews.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow. | Base Camp Trading (Ad)AUPH stock rallies 6% after-hours — here’s whyAugust 19, 2026 | msn.comAurinia Settles Patent Litigation with TevaAugust 19, 2026 | financialpost.comFAurinia, Teva Reach Voclosporin Patent Litigation SettlementAugust 19, 2026 | tipranks.comSee More Aurinia Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aurinia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aurinia Pharmaceuticals and other key companies, straight to your email. Email Address About Aurinia PharmaceuticalsAurinia Pharmaceuticals (NASDAQ:AUPH). is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline. The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S. Food and Drug Administration for the treatment of adult patients with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus. Beyond lupus nephritis, Aurinia is investigating voclosporin in additional indications such as focal segmental glomerulosclerosis (FSGS) and dry eye disease, with several ongoing clinical trials to evaluate safety and efficacy. Founded in the early 1990s, Aurinia is headquartered in Victoria, British Columbia, and maintains a presence in North America to support its clinical and commercial activities. The company’s leadership team comprises experienced professionals in drug development, regulatory affairs and commercial operations, guiding Aurinia through pivotal clinical milestones and into its initial product launch. As Aurinia continues to expand its pipeline and explore partnerships, it remains committed to addressing unmet needs in autoimmune disease management.View Aurinia Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/24 - 08/28From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens3 Retail Stocks to Watch After a Big Consumer Earnings WeekRubrik’s AI Security Bet Could Power the Next Leg HigherIREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings3 Financial Stocks Positioned for the Fed’s Next Move After Jackson HoleNutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape Upcoming Earnings Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026)Snowflake (9/2/2026)Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
